A major challenge in transplantation medicine is controlling the very strong immune responses to foreign antigens that are responsible for graft rejection. Although immunosuppressive drugs efficiently inhibit acute graft rejection, a substantial proportion of patients suffer chronic rejection that ultimately leads to functional loss of the graft 1 . Induction of immunological tolerance to transplants would avoid rejection and the need for lifelong treatment with immunosuppressive drugs 1, 2 . Tolerance to self-antigens is ensured naturally by several mechanisms 3 ; one major mechanism depends on the activity of regulatory T lymphocytes 4, 5 . Here we show that in mice treated with clinically acceptable levels of irradiation, regulatory CD4 + CD25 + Foxp3 + T cells stimulated in vitro with alloantigens induced long-term tolerance to bone marrow and subsequent skin and cardiac allografts. Regulatory T cells specific for directly presented donor antigens prevented only acute rejection, despite hematopoietic chimerism. By contrast, regulatory T cells specific for both directly and indirectly presented alloantigens prevented both acute and chronic rejection. Our findings demonstrate the potential of appropriately stimulated regulatory T cells for future cell-based therapeutic approaches to induce lifelong immunological tolerance to allogeneic transplants. CD4 + CD25 + Foxp3 + regulatory T cells (Tregs) have a crucial role in the prevention of autoimmune 4, 5 and immunoinflammatory 6 diseases, in the regulation of immunity to viral and parasite infections 7, 8 , in the maintenance of maternal tolerance to the fetus 9 and in the inhibition of antitumor immunity 10 . Given their proven physiological role in immune regulation, it is appealing to try to use Tregs to induce immunological tolerance to allografts. We and others have opted to use a strategy in which Tregs are isolated from unmanipulated hosts, cultured in vitro to expand cells with appropriate specificity, and then used to protect allografts in mice. In this fashion, tolerance to bone marrow 11 but not skin allografts 12, 13 has been successfully induced.
Here we evaluated whether immunological tolerance to solid tissue allografts could be induced with a protocol in which mice preconditioned with clinically acceptable levels of irradiation were grafted with allogeneic bone marrow, injected with Tregs and then transplanted with donor skin or heart.
We grafted sublethally irradiated BALB/c (H-2 d ) mice with allogeneic T cell-depleted C57BL/6 (B6, H-2 b ) bone marrow. Three weeks later, the grafted cells had been rejected (Fig. 1a) , demonstrating the non-lymphoablative nature of the preconditioning. To prevent rejection of bone marrow allografts, we next injected the preconditioned BALB/c mice with B6 bone marrow and host-type Tregs stimulated in vitro with donor strain-derived antigen-presenting cells (APCs; Supplementary Note 1 online). The in vitro culture protocol we used allowed for the expansion of CD4 + CD25 + Foxp3 + Tregs (Fig. 1b) . When co-injected with donor bone marrow, these Tregs efficiently protected the allograft from rejection (Fig. 1a) . Thus, we also induced tolerance to fully allogeneic bone marrow grafts in other donor-host combinations, independently of interleukin-10 (IL-10) production by Tregs ( Fig. 1c and Supplementary Fig. 1a ,b online). Using a modified experimental setup, we showed that allograft protection required that effector T cells responded to TGF-b ( Supplementary Fig. 1b) . Finally, we observed no rejection up to 120 d after transplantation (Fig. 1d) , and after engraftment, allogeneic precursors reconstituted all hematopoietic lineages (data not shown).
To be activated, Tregs require antigen-specific stimulation with major histocompatibility complex (MHC) molecule-peptide complexes. However, once activated, these cells exert their suppressor effector function in a non-antigen specific manner in vitro 14 . It was therefore important to evaluate whether Tregs induced generalized immunosuppression in our system. We stimulated B6 Tregs with BALB/c APCs and then injected them into sublethally irradiated B6 recipient with BALB/c and SJL (H-2 s ) bone marrow. Three weeks later, the target bone marrow had reconstituted the hosts' hematopoietic systems, but the third-party SJL bone marrow had been fully rejected (Fig. 1e) . Similarly, Tregs specific for SJL antigens protected SJL but not BALB/c bone marrow from rejection (Fig. 1e) . These results showed that the APCs used in the in vitro cultures determined the specificity of the Tregs in vivo. Moreover, despite the fact that in these mice Tregs had clearly been activated (as they prevented rejection of target bone marrow), they did not protect third-party grafts. Their suppressor effector function was therefore donor specific; they had not induced generalized immunosuppression.
Our data showed that Tregs allow for the establishment of hematopoietic chimerism. We next analyzed whether this chimeric state, in its turn, created a favorable environment for the persistence of injected Tregs. We sublethally irradiated B6 mice, grafted them with allogeneic DBA/2 (H-2 d ) or syngeneic bone marrow, injected them with Tregs previously stimulated with DBA/2 APCs in vitro, and monitored the persistence of the injected Tregs in the mice (Fig. 1f) . We found that substantially more injected Tregs persisted in spleens (but not in blood or lymph nodes; data not shown) of mice that had been injected with donor-type bone marrow. Moreover, these cells had maintained their expression of Foxp3 (Fig. 1f) . These results show that donor hematopoietic cells and donor-specific Tregs mutually favor each other's persistence in vivo.
We wanted to know whether Tregs could also induce tolerance to solid allografts (Fig. 2) . Three weeks after irradiation-the time it took the mice to recover from the preconditioning regimen-B6 animals received allogeneic DBA/2 skin transplants. We injected Tregs, cultured in vitro with donor-type APCs, immediately after irradiation (D0) or just before grafting the skin (D21). In contrast to the results for bone-marrow transplantation, in this setting skin grafts were rapidly rejected (Fig. 2a) . Combined with previously published data 12, 13 , these data suggested that alloantigen-specific Tregs alone do not induce immunological tolerance to allogeneic skin grafts, at least not at the cell doses tested. We therefore next tried to induce tolerance to skin allografts by combining Treg transfer with bone marrow transplantation to prolong Treg persistence. In addition, we expected that the induced chimeric state would contribute to induction of allograft-tolerance. We reconstituted B6 hosts with DBA/2 bone marrow, injected them with in vitro cultured Tregs, and 3 weeks later grafted them with DBA/2 skin. Allogeneic skins did not show any macroscopic signs of rejection during the 100-d observation period, but third-party SJL skins were rapidly rejected (Fig. 2a) . We obtained similar results with five other host-donor combinations and when using mice with substantially lower levels of hematopoietic chimerism ( Supplementary Figs. 2 and 3a,b online). We also assessed whether mice in which Tregs protected a skin allograft from rejection were generally immunosuppressed. SJL mice received B6 bone marrow grafts, B6-specific Tregs and B6 and third-party DBA/2 skins on opposing flanks. Whereas in these mice B6 skins survived, DBA/2 skins were rapidly rejected (Fig. 2b) . Treg-mediated allograft protection was therefore specific, and these cells did not induce generalized immunosuppression.
At 100 d after transplantation, we submitted the skin grafts to histological analysis. The allografts showed only minor signs of rejection (that is, tissue damage), but we observed substantial infiltration by eosinophils and macrophages (Fig. 2d,g ), which were previously observed in chronically rejected skin allografts 15 . Although this observation indicated that the combined Treg-bone marrow chimerism approach had not induced full immunological tolerance to allogeneic skins, 250 d after transplantation, allogeneic grafts still survived ( Supplementary Fig. 3c ). These results demonstrated that the combined Treg-hematopoietic chimerism approach protected allogeneic skin grafts from rejection but did not induce full immunological tolerance to the graft, despite persistent hematopoietic chimerism ( Supplementary Fig. 3d ). It therefore seems unlikely that this protocol will induce long-term protection of tissue allografts in clinical settings.
Graft rejection is initiated when APCs present donor antigens from the transplanted tissue to host lymphocytes, which are then activated to attack the grafted organ via direct cytotoxicity, B cell help and induction of an inflammatory response 16 . Donor antigens from a Cell counts transplant are presented to T cells in two distinct ways, depending on the origin of the APCs 1 . First, donor APCs migrate from the graft to secondary lymphoid organs where they activate host T cells, which therefore recognize donor antigens presented by donor MHC molecules. In contrast to this 'direct' pathway, donor antigens can also be picked up in the transplanted tissue by host APCs, processed and then presented to T cells on self-MHC molecules ('indirect allorecognition'). Whereas acute organ graft rejection has been attributed mainly to direct antigen presentation, chronic rejection is thought to be mediated mostly by T cells specific for indirectly presented donor antigens 1 . In our in vitro culture protocol, we activated host Tregs with donor-type APCs. The injected Treg population was therefore enriched in cells specific for directly presented alloantigens 17 . This may explain why acute skin allograft rejection was efficiently inhibited while chronic rejection still occurred. Tregs specific for indirectly presented alloantigens might, therefore, be able to prevent the chronic immune response to the graft (Supplementary Note 2 online).
To test this hypothesis, we expanded Tregs with (host Â donor)F1 APCs. B6 hosts were transplanted with DBA/2 bone marrow and simultaneously injected with Tregs that had previously been expanded in vitro with (B6 Â DBA/2)F1 APCs. Three weeks later, mice were grafted with DBA/2 (or third-party SJL) skin and allograft survival was monitored. Whereas third-party skins were rejected, 'target' skin grafts survived the whole 100-d monitoring period (Fig. 2c) . We obtained similar results with the reciprocal host-donor combination (Supplementary Fig. 3e) . When, at 100 d after grafting, we subjected the DBA/2 skins to histological analysis, we observed healthy skin without eosinophil or macrophage infiltration (Fig. 2d,h ). The fundamental difference between our results with Tregs specific for directly versus both directly and indirectly presented alloantigens occurred despite similar hematopoietic chimerism in the two experimental conditions (Supplementary Fig. 3d ). These results show that, in combination with hematopoietic chimerism, Tregs specific for directly and indirectly presented alloantigens protected skin allografts from acute and chronic rejection.
We next wanted to know whether Tregs cultured appropriately in vitro would also induce tolerance to cardiac allografts (Fig. 3) . Irradiated host mice received allogeneic bone marrow grafts, in vitro-cultured Tregs and, 3-8 weeks later, allogeneic heart transplants. Whereas in the control groups the hearts were rejected, in treated mice the grafted hearts continued beating for more than 100 d after transplantation (Fig. 3a,b and Supplementary Fig. 4a online) . Prevention of rejection was partially dependent on IL-10 (Supplementary Fig. 1c) . At 100 d after transplantation, the beating hearts were removed for histological analysis. In hearts grafted into mice that had received Tregs specific for directly presented alloantigens only, we observed large, diffuse infiltrates of mononuclear cells and eosinophils, destruction of cardiac muscle fibers, thickening of the intima, arteriosclerosis and extended areas of fibrosis replacing contractile tissue ( Fig. 3e and Supplementary Fig. 4b ), all typical signs of chronic cardiac allograft rejection. All the hearts thus analyzed showed moderate to severe chronic rejection ( Fig. 3c and Supplementary  Fig. 4c ). In contrast, hearts grafted into mice that had received Tregs specific both for directly and indirectly presented alloantigens showed little or no signs of rejection (Fig. 3b,c,f) . This difference occurred despite similar hematopoietic chimerism in both cases (Supplementary Fig. 4d ). These data show that Tregs specific for both directly and indirectly presented donor antigens, in combination with mixed hematopoietic chimerism, prevented both acute and chronic rejection of heart allografts. Our findings show that host CD4 + CD25 + Foxp3 + Tregs, when appropriately stimulated in vitro, can be used to induce immunological tolerance to bone marrow and subsequent skin or cardiac allografts in hosts submitted to non-lymphoablative g-irradiation, preventing both acute and chronic rejection (Supplementary Note 3 online). Suppression of rejection is most likely due to two interdependent mechanisms. First, Tregs suppress host lymphocytes and thus directly contribute to acceptance of the allograft. Second, immunosuppression by Tregs also helps in establishing a chimeric hematopoietic state, allowing the persistence of injected Tregs and contributing to the induction of central and peripheral immunological tolerance of the allografts 18 .
We showed here that mixed hematopoietic chimerism did not induce immunological tolerance to skin and cardiac allografts. This important conclusion is consistent with data on transplantation in mixed hematopoietic chimeras [19] [20] [21] [22] . Transplantation protocols based exclusively on the induction of hematopoietic chimerism will therefore most probably not yield permanent tolerance to, and survival of, allografts.
In conclusion, we have demonstrated that adequately prestimulated Tregs can be used to protect skin and cardiac allografts from acute and chronic rejection. The preconditioning regimen used in our study has a level of toxicity that may be acceptable in clinical settings 23 . However, other protocols aimed at the induction of hematopoietic chimerism are currently being tested in clinical trials [24] [25] [26] and could be used, in combination with injection of in vitro activated Tregs, to replace the one we used. Moreover, human Tregs with indirect specificity can be expanded in vitro 27 . Induction of tolerance to organs or tissues to be taken from live donors should therefore be feasible using our protocol or a modified version thereof. We can also predict that it could, after adaptation, be used to induce tolerance to transplants taken from cadaveric donors.
METHODS
Mice. Sex-matched mice between 6 and 10 weeks of age were used. Mice were purchased from the Centre de Recherche et d'Elevage Janvier. Thy1.1 B6 mice and IL-10-deficient B6 mice were purchased from Charles River. dnTbRIItransgenic B6 mice 28 were bred in our specific pathogen-free animal facility. All Purification and in vitro culture of CD4 + CD25 + T cells. CD4 + CD25 + splenic T cells were purified and cocultured with g-irradiated splenocytes as previously described 17 .
Bone marrow allografts. Bone marrow cells from femurs and tibias were prepared as previously described 17 . 10 7 cells were injected intravenously into g-irradiated mice (5 Gy, 137 Cs source).
Flow cytometry. Hematopoietic reconstitution and Treg persistence were determined by analyzing peripheral blood mononuclear cells (PBMCs) or splenocytes at indicated time points. Erythrocyte-depleted cells were resuspended in 2.4G2 hybridoma supernatant and saturating concentrations of indicated antibodies (Fig. 1) were added. Acquisition was performed on a FACSCalibur or an LSR II cytometer and data were analyzed using CellQuest (BD Biosciences) or FlowJo (Tree Star) software. Foxp3 analysis was performed according to the manufacturer's instructions (eBioscience).
Skin and cardiac transplantation. Skin graft was performed as previously described 29 . Skins were considered rejected if Z70% of the surface was necrotic. Heterotopic heart transplantation was performed in the surgery section of the Institut Fédératif de Recherche 31 animal facility according to a published method 30 with some modifications. Functionality of the transplanted heart was monitored daily by abdominal palpation. Clinical rejection was defined by cessation of palpable heartbeats and confirmed by autopsy. Loss of graft function within 48 h of transplantation was considered as a technical failure (o5%), and animals in which this occurred were omitted from the analysis.
Histological analysis. Skin biopsies and hearts were fixed in 10% buffered formalin and embedded in paraffin. Sections were stained with H&E, Masson's trichrome or Luna's eosinophil stain or using antibodies specific for F4/80. Heart rejection was graded from 0 (none) to 4 (severe): 0, no rejection; 1, slight perivascular mononuclear cell infiltration; 2, intense and/or interstitial mononuclear cell infiltration; 3, intense interstitial mononuclear cell infiltration associated with myocyte loss and slight fibrosis; 4, interstitial mononuclear cell infiltration associated with myocardial necrosis and massive fibrosis.
Statistics. Statistical significance was determined using Student's t-test.
Note: Supplementary information is available on the Nature Medicine website.
